{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.7","upperLimit":"1.4","value":"1.1"},{"groupId":"OG001","lowerLimit":"0.7","upperLimit":"2.1","value":"1.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"TTR is defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (confirmed PR or better).","dispersionType":"95% Confidence Interval","groups":[{"description":"In CE Phase, Participants with RRMM received 0.95 mg/ kg belantamab mafodotin IV infusion as powder for solution once every 3 weeks (Q3W), infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 100 mg nirogacestat BID on day 1, 4, 8 and 15 of 21-day cycles. Treatment was administered until disease progression, intolerable toxicity, informed consent withdrawal, the end of the sub-study or death.","id":"OG000","title":"CE Phase: 0.95mg/kg Belantamab Mafodotin Q3W + Nirogacestat"},{"description":"In CE Phase, Participants with RRMM received 2.5 mg/ kg belantamab mafodotin IV infusion as powder for solution Q3W, infused over 30- 60 minutes on day 1 of 21-day cycles until disease progression, intolerable toxicity, informed consent withdrawal, the end of the sub-study or death.","id":"OG001","title":"CE Phase: 2.5mg/kg Belantamab Mafodotin Q3W"}],"paramType":"MEDIAN","populationDescription":"Safety Population. Only those participants with a confirmed PR or better as the best overall response (i.e., PR, VGPR, CR, and sCR) were assessed for this endpoint.","reportingStatus":"POSTED","timeFrame":"Up to approximately 253 weeks","title":"CE Phase: Time to Response (TTR)","type":"SECONDARY","unitOfMeasure":"Months"}